The estimated Net Worth of Malcolm S Taub is at least 548 千$ dollars as of 14 December 2015. Mr. Taub owns over 41,742 units of Brainstorm Cell Therapeutics stock worth over 2,426$ and over the last 16 years he sold BCLI stock worth over 499,092$. In addition, he makes 46,680$ as Independent Director at Brainstorm Cell Therapeutics.
Malcolm has made over 11 trades of the Brainstorm Cell Therapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 41,742 units of BCLI stock worth 108,529$ on 14 December 2015.
The largest trade he's ever made was selling 575,000 units of Brainstorm Cell Therapeutics stock on 14 September 2009 worth over 149,500$. On average, Malcolm trades about 54,328 units every 99 days since 2009. As of 14 December 2015 he still owns at least 8,666 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Mr. Taub stock trades at the bottom of the page.
Malcolm S. Taub J.D. serves as Independent Director of the Company. Mr. Taub is now the senior partner of Taub & Lewis LLP. Prior to forming that firm in January 2019, since October 2010, Mr. Taub had been a Partner at Davidoff Malito & Hutcher LLP, a full-service law and government relations firm. From 2001 to September 30, 2010, Mr. Taub was the Managing Member of Malcolm S. Taub LLP, a law firm which practiced in the areas of commercial litigation, among other practice areas. Mr. Taub also works on art transactions, in the capacity as an attorney and a consultant. Mr. Taub has also served as a principal of a firm which provides consulting services to private companies going public in the United States. Mr. Taub has acted as a consultant to the New York Stock Exchange in its Market Surveillance Department. Mr. Taub acts as a Trustee of The Gateway Schools of New York and The Devereux Glenholme School in Washington, Connecticut. Mr. Taub has served as an adjunct professor at Long Island University, Manhattan Marymount College and New York University Real Estate Institute. Mr. Taub holds a B.A. from Brooklyn College and a J.D. from Brooklyn Law School. Mr. Taub formerly served on the Board of Directors of Safer Shot, Inc. (formerly known as Monumental Marketing Inc.). Taub’s vast law experience and his demonstrated leadership skills as a managing member of a law firm.
As the Independent Director of Brainstorm Cell Therapeutics, the total compensation of Malcolm Taub at Brainstorm Cell Therapeutics is 46,680$. There are 7 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of 1,639,680$.
Malcolm Taub is 74, he's been the Independent Director of Brainstorm Cell Therapeutics since 2009. There are no older and 18 younger executives at Brainstorm Cell Therapeutics.
Malcolm's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over 1,899,994$ worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth 1,535,874$ . The most active insiders traders include Corp. Accbt、Mike Frankenberger、International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of 206,459$. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth 22,050$.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: